Clinical Trial Update: Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. [Phase 3]

View source ↗

Summary

Phase 3 trial updating ANG receptor-neprilysin inhibition in Chagas cardiomyopathy with reduced ejection fraction (ANSWER-HF) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chagas Cardiomyopathy

Drugs mentioned

• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: University of Sao Paulo General Hospital | Conditions: Chagas Cardiomyopathy | Phase 3 | Status: RECRUITING